The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AWMSG recommends Efmody for CAH in Wales

7 Oct 2022 07:00

RNS Number : 0990C
Diurnal Group PLC
07 October 2022
 

7 October 2022

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

AWMSG recommends Efmody® as treatment option for adolescents and adults with congenital adrenal hyperplasia in Wales

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the All Wales Medicines Strategy Group (AWMSG) has recommended Efmody® (hydrocortisone modified-release hard capsules) as an option for restricted use to treat adolescents and adults with congenital adrenal hyperplasia (CAH) within NHS Wales.

 

The AWMSG's recommendation means that Efmody® is available for use as a second-line treatment option in adolescents with CAH not adequately controlled on maximum guideline doses of immediate-release hydrocortisone; and as a third-line treatment in adults with CAH not adequately controlled on maximum guideline doses of immediate-release hydrocortisone and/or prednisolone. Diurnal will commercially roll-out Efmody® in Wales using its existing sales and marketing infrastructure and supply chain.

 

Efmody® has been available for the treatment of CAH in the UK since launch in October 2021. Efmody® is licensed for the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and older and in adults in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA).

 

Richard Bungay, Interim Chief Executive Officer of Diurnal commented:

"We are delighted that, after a rigorous review, the AWMSG has recognised the potential for Efmody® to address important unmet needs in patients suffering with CAH. Diurnal believes the use of this medicine will improve the lives of adults and adolescents in Wales living with this rare disease."

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Richard Bungay, Interim Chief Executive Officer

 

 

Panmure Gordon (UK) Limited (Nominated Adviser and Corporate Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

 

Corporate Broking: Rupert Dearden

 

 

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

 

Notes to Editors

 

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.com

About congenital adrenal hyperplasia

 

Congenital adrenal hyperplasia (CAH) is an orphan condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase. This enzyme is required to produce the adrenal steroid hormone, cortisol. The block in the cortisol production pathway causes the over-production of male steroid hormones (androgens), which are precursors to cortisol. The condition is congenital (inherited at birth) and affects both sexes. The cortisol deficiency and over-production of male sex hormones can lead to increased mortality, infertility and issues during sexual development including ambiguous genitalia, premature (precocious) sexual development and short stature. Sufferers, even if treated, remain at risk of death through an adrenal crisis.

 

Current therapy for CAH uses a variety of generic glucocorticoid (steroid) preparations including hydrocortisone, dexamethasone and prednisolone, with no standard treatment regimen. Approximately two-thirds of CAH patients are estimated to have poor disease control, leading to elevated androgen levels. The condition is estimated to affect a total of approximately 41,000 patients in Europe.

 

About Efmody® (hydrocortisone modified-release hard capsules)

 

Efmody® is a preparation of hydrocortisone that has been specifically designed to mimic the circadian rhythm of cortisol when given in a twice-a-day "toothbrush" regimen (administered last thing at night before sleep and first thing in the morning on waking) to control androgen excess and chronic fatigue in patients with diseases of cortisol deficiency. The first indication for Efmody® is Congenital Adrenal Hyperplasia (CAH) in adults and adolescents (children older than 12 years of age). Efmody® has been extensively studied in 239 human subjects including 138 CAH patients who have taken part in clinical trials in Europe and the US.

 

The MHRA and European Commission marketing authorisation approval of Efmody ® was based on a Phase 3 study conducted in a total of 122 patients enrolled across 11 clinical sites, including sites in Great Britain, the largest ever interventional clinical trial completed in CAH. The Phase 3 data was supported by detailed analysis of data from an open-label safety extension study for patients completing treatment in the Phase 3 study, which is assessing the impact of treatment with Efmody ® over an extended period, with a number of patients on this trial having been treated for over 5 years. Summary of Product Characteristics (SmPC) for UK including Northern Ireland) can be found here.

 

 

 

Date of Preparation: October 2022 Code: CH EU-GLO-0011

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDZMGGZVLGZZZ
Date   Source Headline
6th Mar 202011:22 amRNSProposed Placing
5th Mar 20204:41 pmRNSDirectorate Change
28th Feb 20207:30 amEQSHardman & Co Research: Diurnal (DNL): . and more to come (news flow)
25th Feb 20203:06 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 202011:00 amRNSPrice Monitoring Extension
17th Feb 20201:46 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNSUS FDA Accepts NDA Application for Alkindi
11th Feb 20207:00 amRNSInterim Results
20th Jan 20207:00 amRNSBusiness and trading update
13th Jan 20207:00 amRNSNotice of Interim Results
13th Jan 20207:00 amRNSHolding(s) in Company
10th Jan 20203:45 pmRNSDirector Dealings and Issue of Equity
10th Jan 20203:44 pmRNSIssue of Long-Term Incentive Plan awards
16th Dec 201911:46 amRNSDirector Dealings
16th Dec 20197:00 amRNSChronocort MAA Submitted in Europe
2nd Dec 20192:28 pmRNSShare Option Exercise and Issue of Equity
2nd Dec 20197:01 amRNSHolding(s) in Company
2nd Dec 20197:00 amRNSAlkindi New Drug Application Submitted to US FDA
26th Nov 201910:42 amRNSDirector Dealings and Issue of Equity
26th Nov 20197:15 amEQSHardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
21st Nov 20191:08 pmRNSResults of Annual General Meeting
21st Nov 20197:00 amRNSAGM Statement
20th Nov 20197:00 amRNSSuccessful outcome of testosterone clinical study
8th Nov 20197:00 amRNSVesting of LTIP awards
5th Nov 20197:30 amEQSHardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
21st Oct 20196:23 pmRNSIssue of Equity
21st Oct 20191:09 pmRNSDirector Dealings
8th Oct 201911:26 amRNSPosting of Annual Report and AGM Notice
24th Sep 20197:00 amRNSResults for the year ended 30 June 2019
7th Aug 201911:04 amRNSDirector Dealings
5th Aug 201912:27 pmRNSDirector/PDMR Shareholding
26th Jul 20194:32 pmRNSHolding(s) in Company
8th Jul 20192:07 pmRNSDirector Dealings and Issue of Equity
3rd Jul 20197:00 amRNSMarket Authorisation Application in Australia
26th Jun 20193:57 pmRNSHolding(s) in Company
24th Jun 20199:39 amRNSDirector Dealings
21st Jun 20193:40 pmRNSHolding(s) in Company
21st Jun 20193:35 pmRNSHolding(s) in Company - Replacement
21st Jun 201910:18 amRNSChange of Auditor
19th Jun 20194:08 pmRNSHolding(s) in Company
18th Jun 20195:30 pmRNSHolding(s) in Company
18th Jun 20192:03 pmRNSDirector Dealings
17th Jun 201912:05 pmRNSDirector Dealings
14th Jun 201912:39 pmRNSResult of General Meeting and Issue of Equity
14th Jun 20197:00 amRNSResult of Open Offer
28th May 20197:00 amRNSPlacing, Open Offer and Notice of General Meeting
9th May 20197:00 amRNSIntent to Submit for MAA tendered to the EMA
2nd May 20193:29 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.